EMBC · Embecta Corp.
$3.37
-0.07 (-2.03%)
At close · Jul 21
Market Cap
$192.81M
Shares
59.33M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.08B
-3.8%
FY2025
Net Income
$95.4M
+21.8%
FY2025
Gross Margin
62.64%
-2.8pp
FY2025
Operating Margin
22.41%
+7.6pp
FY2025
Diluted EPS
$1.62
+20.9%
FY2025
Operating Cash Flow
$191.7M
+437%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $1.02B – $1.04B | $1.04B | $1.08B | $1.12B | $1.12B | $1.13B | $1.17B | $1.09B | |
| — | $397.4M | $403.6M | $387.9M | $370.9M | $354.6M | $364.9M | $322.9M | |
| — | $645.1M | $676.8M | $735.2M | $749.9M | $774.9M | $800.4M | $762.6M | |
| — | — | 62.64% | 65.46% | 66.91% | 68.61% | 68.69% | 70.25% | |
| — | $19M | $37.3M | $78.8M | $85.2M | $66.9M | $63.3M | $61.4M | |
| — | $325.1M | $332M | $365.1M | $341.3M | $294.8M | $240.3M | $214.7M | |
| — | — | $1.1M | $1.1M | $1.2M | $700K | $300K | $300K | |
| — | — | $40.7M | $36.2M | $32.6M | $31.7M | $38.3M | $38.3M | |
| — | $1.1M | $38M | — | — | — | — | — | |
| — | $376.3M | $434.7M | $568.4M | $528.4M | $465.3M | $308.4M | $276.1M | |
| — | $268.8M | $242.1M | $166.8M | $221.5M | $309.6M | $492M | $486.5M | |
| — | — | 22.41% | 14.85% | 19.76% | 27.41% | 42.22% | 44.82% | |
| — | — | $282.8M | $203M | $254.1M | $341.3M | $530.3M | $524.8M | |
| — | $200K | $1.5M | -$10.3M | -$8.8M | -$6.8M | $2.9M | -$700K | |
| — | $169.6M | $136.3M | $44.2M | $105.7M | $256.6M | $494.9M | $485.8M | |
| — | $57.7M | $40.9M | -$34.1M | $35.3M | $33M | $80.1M | $58.2M | |
| — | $111.9M | $95.4M | $78.3M | $70.4M | $223.6M | $414.8M | $427.6M | |
| — | — | 8.83% | 6.97% | 6.28% | 19.8% | 35.6% | 39.39% | |
| — | $129M | $101.4M | $94.6M | $86.2M | $159.4M | $405.9M | $444M | |
| USD/shares | — | — | $1.64 | $1.36 | $1.23 | $3.92 | $7.28 | $7.50 |
| USD/shares | — | — | $1.62 | $1.34 | $1.22 | $3.89 | $7.28 | $7.50 |
| shares | — | — | 58.31M | 57.68M | 57.25M | 57.02M | 57.01M | 57.01M |
| shares | — | — | 58.92M | 58.33M | 57.76M | 57.46M | 57.01M | 57.01M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2025: $112.5M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.28×
Medical Instruments & Supplies median 2.10×
EV/EBIT
4.96×
Medical Instruments & Supplies median 28.56×
P/E (TTM)
1.72×
Medical Instruments & Supplies median 36.99×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| United States | $579,100,000 | $607,200,000 | $601,400,000 | $600,300,000 | $609,400,000 | $563,000,000 |
| Non Us | $501,300,000 | $515,900,000 | $519,400,000 | $529,200,000 | $555,900,000 | $522,500,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Pen Needles | $784,100,000 | $844,400,000 | $829,200,000 | $824,600,000 |
| Safety | $137,800,000 | $129,400,000 | $126,300,000 | $119,600,000 |
| Syringes | $124,600,000 | $126,200,000 | $138,100,000 | $156,000,000 |
| Manufacturing Facility | $19,900,000 | $12,800,000 | $13,000,000 | $15,000,000 |
| Product And Service Other | $14,000,000 | $10,300,000 | $14,200,000 | $14,300,000 |
Key facts
CIK
1872789
CUSIP
29082K105
13F (30d)
53 filings
52 filers
Visit website
Investor relations